Filter By Category
Archives
Share on -
EFANESOCTOCOG ALFA
Generic Name: EFANESOCTOCOG ALFA
ABSTRACT -
Efanesoctocog alfa is an extended-half-life recombinant factor VIII fusion protein used for hemophilia A prophylaxis and treatment of bleeding under approved product labeling.
DOSAGE -
Use labeled IU/kg dosing for prophylaxis, on-demand treatment, and perioperative management. Adjust based on factor VIII activity, bleeding severity, and clinical response.
SIDE EEFECTS -
- Headache
- Arthralgia or musculoskeletal pain
- Rash
- Infusion-related reactions
- Laboratory inhibitor development
ALLERGIC REACTIONS -
These symptoms may indicate an allergic reaction and require medical attention.
- Hypersensitivity to factor VIII product or excipients
- Urticaria, chest tightness, wheezing, hypotension, or anaphylaxis
DRUG INTEACTIONS-
- No broad CYP interactions; hemostatic agents require specialist coordination
- Emicizumab or bypassing agents require careful hemophilia-center guidance
- Anticoagulants and antiplatelets increase bleeding considerations
PREAUTONS–
- Monitor factor VIII levels and inhibitor development
- Use under hemophilia specialist guidance
- Document lot numbers for traceability
WARNINGS –
- Neutralizing antibodies/inhibitors and serious hypersensitivity can occur
- Inadequate dosing may fail to control bleeding
Share on -
. Developed by